Phase III Trial Shows Promise for Hetlioz in Treating Delayed Sleep-Wake Phase Disorder
How Does Tasimelteon Reset the Body Clock?
A late-stage clinical trial of Hetlioz (tasimelteon) demonstrated a significant advancement in sleep timing for adults with delayed sleep-wake phase disorder, moving sleep onset an average of 42.5 minutes earlier compared to just 5.4 minutes with placebo. The results, announced by the drug’s developer, indicate the circadian regulator met its primary endpoint in the phase III study, strengthening the case for expanding the drug’s approved use beyond its current indication for non-24-hour sleep-wake disorder in blind individuals. The findings suggest a potential path toward a new FDA submission for this additional indication.
Health news
Vegan Diets May Reduce Gut Bacteria Diversity, Study Finds
Music with beats cuts stress hormone more than pink noise
Epigenetic Shifts Can Trigger Liver Cancer Without DNA Damage
Blood Clots and Brain Tumors Linked by Overactive PlateletsThe trial focused on adult participants whose internal body clocks were misaligned with conventional sleep schedules, a condition that often leads to chronic insomnia and daytime impairment. By targeting melatonin receptors involved in regulating the circadian rhythm, tasimelteon helps realign the body’s internal clock with the external environment. Researchers noted that the magnitude of the shift observed in the active treatment group was both statistically and clinically meaningful, offering a measurable improvement over placebo. The study design included objective measures of sleep timing, reinforcing the reliability of the outcome. No new safety concerns were reported during the trial, maintaining the drug’s established tolerability profile.
What Are the Next Steps for FDA Approval?
Tasimelteon functions as a melatonin agonist, binding to MT1 and MT2 receptors in the brain’s suprachiasmatic nucleus, the master regulator of circadian rhythms. Unlike sedatives that induce drowsiness, it works by signaling the body that it is time to sleep, thereby facilitating a natural shift in sleep timing. In the trial, participants took the drug in the evening, consistent with its mechanism of supporting nocturnal melatonin signaling. This approach aims to correct the underlying biological misalignment rather than merely masking symptoms. The 42.5-minute advance in sleep onset reflects a meaningful adjustment for individuals whose sleep is typically delayed by hours relative to societal norms.
With the primary endpoint achieved, the next phase involves compiling the full dataset for submission to the U. S. Food and Drug Administration as part of a supplemental new drug application. The goal is to secure approval for tasimelteon as a treatment for delayed sleep-wake phase disorder in sighted adults, broadening its therapeutic reach. If approved, it would offer a targeted pharmacological option for a condition currently managed primarily through behavioral strategies like light therapy and sleep scheduling. Experts suggest that having an FDA-approved drug could improve access and consistency of care, particularly for patients who struggle with adherence to non-pharmacological regimens. The timeline for submission and review will depend on the completeness of the data package and agency feedback.
What is delayed sleep-wake phase disorder? It is a circadian rhythm disorder where a person’s sleep is delayed by two or more hours beyond conventional bedtimes, leading to difficulty waking up in the morning and functioning during typical daytime hours.
Frequently Asked Questions
How effective was Hetlioz in the trial? Hetlioz shifted sleep onset an average of 42.5 minutes earlier, compared to a 5.4-minute shift in the placebo group, meeting the study’s primary endpoint.
Is Hetlioz already approved for any use? Yes, Hetlioz is currently FDA-approved for the treatment of non-24-hour sleep-wake disorder in totally blind individuals who lack light perception.